CD274 and head and neck squamous cell carcinoma: The inhibitor drugs targeting PDL1, pembrolizumab and pembrolizumab, have been approved for use in many solid cancer treatments, including the first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) (10).